Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Merck reports positive results from the first two phase 3 CORALreef trials of enlicitide decanoate to treat adults with hyperlipidemia: Rahway, New Jersey Tuesday, June 10, 2025, ...

Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.